Millions See Cost Savings Under the Inflation Reduction Act

The Inflation Reduction Act (IRA) made significant improvements to Medicare prescription drug access and affordability, including by restructuring the Part D benefit to limit enrollee expenses. Those changes began in January 2024, when the IRA eliminated cost sharing in the catastrophic coverage phase. This has effectively held enrollee spending to roughly $3,400 in 2024. Starting in 2025, the IRA sets a lower, uniform cap at $2,000, which will be indexed annually for growth in Part D.

A new report from the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Planning and Evaluation (ASPE) examines the impact of the catastrophic coverage phase elimination on beneficiary spending as of June 30, 2024, including the number affected, their demographic characteristics, and their savings. Among the key findings:

  • Nearly 1.5 million enrollees reached the catastrophic phase of the Medicare Part D benefit by June 30, 2024. From the time their spending reached the cap through December 31, 2024, these enrollees—and others who hit the cap before the end of the year—have no cost-sharing on covered prescription drugs.
  • More than 500,000 Part D enrollees who did not have the Low-Income Subsidy (LIS) hit the cap in the first half of the year and saved a total of $979 million, with average savings of $1,802 per enrollee. These savings will likely continue over the remainder of the year.
  • LIS enrollees were more than four times as likely to reach the catastrophic phase by June 30 than non-LIS enrollees. Although most would have had no cost-sharing in the catastrophic phase even before the IRA took effect, those with incomes between 135 and 150 percent of the Federal Poverty Level (FPL) would have had some cost sharing, as they only qualified for Partial LIS prior to the IRA.
  • Proportions of Medicare Part D enrollees hitting the 2024 cap by June 30 were higher for enrollees under age 65, American Indian and Alaska Native enrollees, and African American enrollees.
  • Enrollees hitting the cap in the first half of the year had particularly high out-of-pocket spending on cancer drugs. The highest out-of-pocket costs were for the generic version of the cancer drug lenalidomide, with average out-of-pocket costs of $2,921; the branded version, Revlimid, was also in the top ten with $1,984 in average out-of-pocket costs. The other eight drugs are all brand drugs, and only one, Vyndamax, is for a condition other than cancer (cardiovascular disease).
  • More enrollees will hit the cap during the second half of the year, generating additional savings.
  • 4.6 million enrollees would have hit the $2,000 out-of-pocket limit that will take effect in 2025.

The cap on out-of-pocket spending for Part D enrollees is only one of the IRA policies helping lower beneficiary costs. Other important provisions include:

  • Consumer rebates on drugs with prices that increase faster than inflation (effective in 2022 for Part D and in 2023 for Part B).
  • A $35 limit on beneficiary cost-sharing for a month’s supply of insulin (effective in 2023 for Part D and Part B).
  • Elimination of cost-sharing for recommended Part D vaccines (effective in 2023)
  • LIS eligibility expansion (effective in 2024).
  • Medicare drug price negotiation (effective in 2026 for Part D and in 2028 for Part B).

An earlier ASPE report estimated that beneficiary out-of-pocket savings would total $7.4 billion in 2025, once these reforms were in place.

Millions See Cost Savings Under the Inflation Reduction Act

Share:

View the Latest Posts:

Medicare Isn’t “Set It and Forget It”: 7 Life Changes That Should Trigger a Coverage Review

Choosing Medicare coverage is an important decision—but it is not necessarily a one-time decision. The coverage that worked well when you first enrolled may not continue to fit as your health, prescriptions, finances or lifestyle change. Unfortunately, many people automatically renew their coverage year after year without checking whether it still meets their needs. Here are seven life changes that may signal it is time for a Medicare coverage review. 1. You Were Prescribed a New Medication Prescription needs can change quickly. A new medication may not be covered by your current plan, may fall into a different cost tier or may require prior authorization. Even when a medication is covered, the amount you pay can vary between plans and pharmacies. Before making a coverage decision, consider reviewing: Your complete prescription list Dosages and frequency Preferred pharmacies Mail-order options Plan formularies and medication restrictions A plan with a low premium

Medicare Preventive Benefits: Are You Taking Advantage of What Medicare Covers?

When most people think about Medicare, they think about coverage for doctor visits, hospital stays, prescriptions, and medical treatment. But Medicare also provides access to a wide range of preventive services designed to help beneficiaries stay healthier and identify potential health concerns earlier. Understanding these benefits can help you get more value from your Medicare coverage—and may help you have better conversations with your healthcare providers throughout the year. Medicare Is About More Than Treating Illness Preventive healthcare focuses on identifying health risks before they become more serious. Medicare Part B covers numerous preventive and screening services, including certain exams, vaccines, laboratory tests, screenings, counseling, and health-monitoring programs. Depending on eligibility and other Medicare requirements, preventive services may include: Cardiovascular disease screenings Diabetes screenings Colorectal cancer screenings Mammograms Prostate cancer screenings Lung cancer screenings Bone mass measurements Glaucoma screenings Depression screenings Certain vaccinations Tobacco-use counseling Obesity behavioral therapy Medical nutrition

Why Every Medicare Beneficiary Should Take Advantage of Their Annual Wellness Visit

When most people hear the words “annual checkup,” they assume they’re talking about a physical exam. Under Medicare, however, there’s an important difference between an Annual Wellness Visit and a routine physical—and understanding that difference can help you stay healthier while avoiding unexpected costs. As a Medicare beneficiary, your Annual Wellness Visit is one of the most valuable preventive benefits available to you. What Is an Annual Wellness Visit? The Medicare Annual Wellness Visit is a preventive appointment designed to help you and your healthcare provider create or update a personalized plan for maintaining your health. Rather than diagnosing illnesses, the visit focuses on prevention and identifying potential health risks before they become serious. Medicare covers this visit once every 12 months for eligible beneficiaries. During your appointment, your provider may: Review your medical and family history Update your list of medications Check your height, weight, blood pressure, and other

Medicare Myths That Could Cost You Money in Retirement

For many Americans, Medicare is one of the most valuable benefits they’ll ever receive. Yet every year, countless individuals make important healthcare decisions based on misinformation or outdated advice. The truth is, understanding how Medicare works doesn’t have to be overwhelming—but separating fact from fiction is essential. Let’s take a look at some of the most common Medicare myths and the facts every beneficiary should know. Myth #1: Medicare Covers Everything One of the biggest misconceptions is that Medicare pays for all healthcare expenses. While Medicare provides excellent coverage, it does not pay for every medical cost. Depending on the services you receive, you may still be responsible for deductibles, copayments, coinsurance, prescription drug costs, dental care, vision services, hearing aids, and long-term custodial care. Understanding where coverage ends can help you prepare for future healthcare expenses. Myth #2: You Should Automatically Enroll in the First Plan You See Every